Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21750| Title: | A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. | Austin Authors: | Xiong, Chengjie;Luo, Jingqin;Agboola, Folasade;Li, Yan;Albert, Marilyn;Johnson, Sterling C;Koscik, Rebecca L;Masters, Colin L ;Soldan, Anja;Villemagne, Victor L ;Li, Qiao-Xin;McDade, Eric M;Fagan, Anne M;Massoumzadeh, Parinaz;Benzinger, Tammie;Hassenstab, Jason;Bateman, Randall J;Morris, John C | Affiliation: | Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA The Florey Institute, University of Melbourne, Melbourne, Australia Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia Department of Medicine, University of Melbourne, Melbourne, Australia Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA Siteman Cancer Center Biostatistics Core Washington University School of Medicine, St. Louis, MO, USA Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA Wisconsin Alzheimer's Institute and Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA Geriatric Research Education and Clinical Center, William S Middleton Veterans Memorial Hospital, Madison, WI, USA |
Issue Date: | Nov-2019 | Date: | 2019-09-07 | Publication information: | Alzheimer's & Dementia 2019; 15(11): 1448-1457 | Abstract: | Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging-based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/21750 | DOI: | 10.1016/j.jalz.2019.06.4955 | Journal: | Alzheimer's & Dementia | PubMed URL: | 31506247 | Type: | Journal Article | Subjects: | Alzheimer disease Amyloid imaging with positron emission tomography (PET) using the [(11)C] benzothiazole tracer Biomarkers Cerebrospinal fluid (CSF) Magnetic resonance imaging (MRI) volumetrics Pittsburgh Compound-B (PIB) Preclinical stages Prevention trials |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.